Compare PTCT & RDNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | RDNT |
|---|---|---|
| Founded | 1998 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.7B |
| IPO Year | 2006 | 1996 |
| Metric | PTCT | RDNT |
|---|---|---|
| Price | $62.76 | $61.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 5 |
| Target Price | $79.41 | ★ $86.00 |
| AVG Volume (30 Days) | ★ 1.0M | 820.8K |
| Earning Date | 05-12-2026 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | N/A |
| EPS | ★ 7.78 | N/A |
| Revenue | $264,734,000.00 | ★ $1,616,630,000.00 |
| Revenue This Year | N/A | $12.24 |
| Revenue Next Year | $21.65 | $9.52 |
| P/E Ratio | $8.14 | ★ N/A |
| Revenue Growth | ★ 36.19 | 13.05 |
| 52 Week Low | $35.95 | $45.00 |
| 52 Week High | $87.50 | $85.84 |
| Indicator | PTCT | RDNT |
|---|---|---|
| Relative Strength Index (RSI) | 21.26 | 35.11 |
| Support Level | $57.74 | $53.23 |
| Resistance Level | $63.19 | $74.09 |
| Average True Range (ATR) | 2.77 | 3.35 |
| MACD | -0.57 | -0.50 |
| Stochastic Oscillator | 8.82 | 0.87 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.